DRREDDY - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 2.8
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry could be considered around 1,165 ₹ – 1,180 ₹, utilizing the support zone near the 50 DMA. An initial stop-loss order should be placed at 1,140 ₹ to protect profits. A potential resistance level lies around 1,210 ₹ - 1,230 ₹ which would represent a target for profit taking if the price action validates this breakout. Overall, while momentum is positive, the high valuation warrants caution and careful monitoring of future developments in the vaccine distribution timeline.
✅ Positive
The stock is trading near its recent high of 1,415 ₹, and the DII holding has increased significantly, suggesting buying pressure from domestic investors. Volume is elevated compared to the weekly average, indicating substantial interest in the shares.
⚠️ Limitation
Despite the positive momentum, the extremely high P/E ratio (148) relative to the industry (34.8) raises concerns about overvaluation and potential downside risk if growth expectations are not met. The negative PAT from the previous quarter is also a factor to consider.
📉 Company Negative News
The recent news regarding the Dengue shot Qdenga reaching India’s private market via Dr. Reddy’s, while potentially positive for future revenue streams, does not directly translate into current price action and is several years away from materializing. The Upstox report on the Upstox IPO setting a price band also introduces another potential competing stock with considerable investor attention.
📈 Company Positive News
The recent agreement to distribute the Dengue vaccine in India provides a specific near-term positive catalyst, though the timeline (2027) remains distant. This represents a clear expansion into a significant market and solidifies Dr. Reddy’s position within the healthcare sector.
🏭 Industry
The pharmaceutical industry is currently experiencing growth driven by increasing demand for generics and biosimilars globally, coupled with rising healthcare expenditure. However, competition remains intense, especially in established markets like India, necessitating continuous innovation and strategic partnerships.